Polyplus, a solutions provider for manufacturing of Advanced Therapeutic Medicinal Products from research to commercial grade, has acquired Bio Elpida, a French biotechnology contract development and manufacturing (CDMO) company providing pre-clinical and clinical development services for cell therapy and biologics. The teams will integrate strategically to strengthen the supply chain for GMP formulation and filling at Polyplus.
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF ) ( “BioVaxys”), today announced that its cancer vaccine manufacturing partner, Bio Elpida, in Lyon ( France ), has crossed milestones in the development of the bioproduction process of BVX-0918A, BioVaxys' ovarian cancer vaccine, and that it is entering the next development phase of the manufacturing process.